The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes

Su Ee Wong, Chrishan Surendran Samuel, Darren J Kelly, Yuan Zhang, Gavin Becker, Timothy D Hewitson

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)


The end-point of diabetic renal disease is the accumulation of excess collagen (fibrosis/sclerosis). A number of studies have shown that the hormone relaxin (RLX) ameliorates progression of renal and non-renal fibrosis. This study assessed the anti-fibrotic potential of RLX in streptozotocin (STZ)-treated transgenic mRen-2 rats, an accelerated model of type 1 diabetes. Eight-week old hyperglycaemic (STZ-treated at week-6) and normoglycaemic (STZuntreated) animals were treated with or without recombinant human gene-2 (H2) RLX for 4- weeks (by osmotic mini-pumps) and assessed for various parameters at 12-weeks of age. Hyperglycaemic mRen-2 rats had elevated kidney weight/body weight ratio, glomerular filtration rate (GFR), albumin excretion rate (AER), interstitial collagen I and glomerulosclerosis (all p
Original languageEnglish
Pages (from-to)1029 - 1038
Number of pages10
JournalProtein and Peptide Letters
Issue number9
Publication statusPublished - 2013

Cite this